. . . . "Oral bioavailability is 83%."@en . . "Valdecoxib is eliminated predominantly via hepatic metabolism with less than 5% of the dose excreted unchanged in the urine and feces. About 70% of the dose is excreted in the urine as metabolites, and about 20% as valdecoxib N-glucuronide."@en . . "Humans and other mammals"@en . . . . . . . . . . . "withdrawn"@en . "98%"@en . . " "@en . . . "Valdecoxib"@en . . "8-11 hours"@en . . . . . . . . . . . . "* 86 L"@en . . "Eswaraiah Sajja, Anumula Reddy, Aalla Sampath, Gilla Goverdhan, \"Process for preparing crystalline form A of valdecoxib.\" U.S. Patent US20050272787, issued December 08, 2005."@en . . . . . . "investigational"@en . "For the treatment of osteoarthritis and dysmenorrhoea"@en . . . . . "Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about possible increased risk of heart attack and stroke."@en . "Symptoms following acute NSAID overdoses are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression and coma may occur, but are rare."@en . . "* oral cl=6 L/h * 6 \u2013 7 L/h [In patients undergoing hemodialysis] * 6 \u2013 7 L/h [healthy elderly subjects]"@en . . . "Both COX-1 and COX-2 catalyze the conversion of arachidonic acid to prostaglandin (PG) H2, the precursor of PGs and thromboxane. Valdecoxib selectively inhibits the cyclooxygenase-2 (COX-2) enzyme, important for the mediation of inflammation and pain. Unlike non-selective NSAIDs, valdecoxib does not inhibit platelet aggregation."@en . . . . . . "181695-72-7"@en . . . .